Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

Opposition New Democrats continued their coordinated efforts to attack the government over health care, this time focusing on ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...

Researchers also found that one in 14 day case surgery patients have new or worse chronic pain within three months of their ...

In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with doctors about their specialties' biggest ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

On the 6th, the Department of Urology at the Catholic University of Korea's Seoul St. Mary's Hospital (Professor Lee Ji-yeol) ...

Deion Sanders hits reset at Colorado without 'Louis Luggage' recruiting strategy originally appeared on The Sporting News.

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.